rp-6306
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 23, 2021 (NCT04855656)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06107868 | Phase 1 | Dec 4, 2023 | University of Toronto |
| NCT05605509 | Phase 2 | Dec 31, 2022 | British Columbia Cancer Agency, Canadian Cancer Trials Group, Repare Therapeutics, University of Toronto |
| NCT05601440 | Phase 2 | Dec 31, 2022 | British Columbia Cancer Agency, Canadian Cancer Trials Group, University of Ottawa, University of Toronto |
| NCT05147272 | Phase 1 | Dec 31, 2021 | Repare Therapeutics |
| NCT05147350 | Phase 1 | Dec 31, 2021 | Repare Therapeutics |
| NCT04855656 | Phase 1 | Apr 23, 2021 | Repare Therapeutics |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Repare Therapeutics | For profit | 4 | 3 | 2 | 2021 |
| University of Toronto | Academic/Hospital | 3 | 1 | 2 | 2022 |
| British Columbia Cancer Agency | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 1 | 2022 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1